| This week's sponsor is Premier Research. | | | Powerful Partners: The Growing Role of Patient Advocates
We salute patient advocates on the vital role they play on Rare Disease Day, and every day. Read our white paper on how these patient groups are changing clinical research. Premier Research. It's what we do. Best. |
Today's Rundown Amgen veteran Reshma Kewalramani promoted to Vertex CMO Yale Cancer Center joins BMS’ II-ON immuno-oncology network 1 year after IPO, ObsEva’s IVF drug shows promise in phase 3 [Sponsored] Launch Excellence: Is It Achievable? Summit’s DMD drug cuts muscle inflammation in POC trial AstraZeneca taps Pelago for drug-protein interaction assay A CRISPR cure for Huntington’s? BenevolentAI's Proximagen buy creates first AI firm capable of entire drug R&D Featured Story | | | Monday, February 26, 2018 Having spent just a year at Vertex, and after a major 12-year stint at Amgen, Reshma Kewalramani, M.D., has been promoted to chief medical officer and EVP of global medicines development and medical affairs at the company. |
|
|
Top Stories Monday, February 26, 2018 Bristol-Myers Squibb wants a bird’s-eye view of discoveries in cancer immunotherapy, and a few years ago launched an initiative to stay close to top academic centers working in the area. Now, it’s added Yale Cancer Center and leading lung cancer researcher Roy Herbst, M.D., Ph.D., to its list of participants. Monday, February 26, 2018 ObsEva's nolasiban, a drug designed to improve pregnancy rates in IVF procedures, met its primary endpoint in topline phase 3 data. Monday, February 26, 2018 Excellence is within reach. Learn how to earn distinction in today’s competitive healthcare marketplace by delivering the right drug to the right patient at the right time. Monday, February 26, 2018 Summit Therapeutics has posted further data from the ongoing phase 2 trial of ezutromid. The latest analysis links the utrophin modulator to a statistically significant decline in muscle inflammation in boys with Duchenne muscular dystrophy (DMD). Monday, February 26, 2018 AstraZeneca has teamed up with Pelago Bioscience to examine how drug candidates interact with protein targets. The collaboration will apply Pelago’s cellular assay technology to the screening and safety assessment of assets in AstraZeneca’s preclinical pipeline. Monday, February 26, 2018 Scientists in Poland are fine-tuning a Cas9 “nickase”—an enzyme that can cut one strand of DNA instead of both strands—potentially providing a safe way to edit out the gene that causes Huntington's. Monday, February 26, 2018 Ken Mulvany left his CEO post at Proximagen to found artificial intelligence firm BenevolentAI in 2013. Now, having successfully grown the business into a bioinformatics unicorn, he has gone back and bought up part of his former employer. Resources Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Sponsored by: MK&A There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now! Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA PEGS: The Essential Protein Engineering Summit April 30-May 4 | Boston, MA Partnering for Growth 2018 March 20th | 7:30 am-6 pm
March 21st | 7:30 am-1:15 pm Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 